Nemucore Medical Innovations is here to bring you the future of cancer care. Theyâre developing a new type of targeted therapy that ââŚrelies on knowledge from an RNA-based diagnostic instead of more traditional DNA-based diagnostics to determine if a patient with cancer is a candidate for our targeted therapy.â They believe that this type of diagnostic will help unlock targeted therapies for the 70% of cancer patients who do not have âdruggableâ genetic mutations in their DNA. So far, Nemucore has raised $7M from foundation grants and the National Cancer Institute; they have over 57 investors; and leading experts at Memorial Sloan Kettering and Moffitt Cancer Centers are set to perform their clinical trial. Plus, their leadership team has over 100 years of biopharmaceutical experience. The bottom line? Nemucore wants, with this campaign, to âcure AML together and open a new future of cancer care.â Source
No articles found.
Acer is a pharmaceutical company focused on the acquisition, development and comme...
Acer is a pharmaceutical company focused on the...
Valeritas is a commercial-stage medical technology company focused on improving he...
Valeritas is a commercial-stage medical technol...
After a good friend contracted HIV, I thought how could this happen? I was both sh...
After a good friend contracted HIV, I thought h...
Ligand is a biopharmaceutical company focused on developing or acquiring technolog...
Ligand is a biopharmaceutical company focused o...
Galapagos develops therapies with proprietary, novel modes-of-action. Filgotinib, ...
Galapagos develops therapies with proprietary, ...
Recro Pharma (NASDAQ: REPH) is a revenue generating specialty pharmaceutical compa...
Recro Pharma (NASDAQ: REPH) is a revenue genera...
Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is...
Merrimack is a biopharmaceutical company based ...
Join the National Investor Network and get the latest information with your interests in mind.